pharma industry news and analysis | firstword pharma
No description
Total Visits
Avg. Visit Duration
Pages per Visit
Bounce Rate
Registration Date
| Month | Traffic |
|---|---|
| 2025-02 | 105.58 |
| 2025-03 | 158.882 |
| 2025-04 | 205.174 |
| Source | Traffic Share |
|---|---|
| direct | 51.31% |
| search | 37.66% |
| referrals | 6.64% |
| social | 2.65% |
| 0.95% | |
| paid referrals | 0.79% |
| Region | Percentage |
|---|---|
| United States | 35.38% |
| India | 25.15% |
| United Kingdom | 9.54% |
| KR | 3.32% |
| Canada | 1.82% |
| Keyword | Traffic | Volume | CPC |
|---|---|---|---|
| vyndamax or tafamidis or amvuttra or vutrisiran | 18 | 180 | $0.00 |
| novavax or nanoflu or nvx-cov2373 or matrix-m | 238 | 2,380 | $0.00 |
| navacaprant | 81 | 810 | $3.65 |
| bridgebio or attruby or nulibry or encaleret or "bbp-418" or infigratinib or "bbp-812" or acoramidis or fosdenopterin | 0 | 0 | $0.00 |
| pfizer and vaccine | 87 | 870 | $0.00 |